SCHEMBL27161628

SCHEMBL27161628

CC(C)CCN1CCC2(CC1)CCN(S(=O)(=O)c1ccc(N3CCC(F)(F)CC3)nc1)CC2

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 4/20 0.50
▸ KDM4E B2RXH2 3/20 0.50
▸ CYP2D6 P10635 3/20 0.47
▸ ALDH1A1 P00352 6/20 0.46
▸ SMN1; SMN2 Q16637 4/20 0.45
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ HSD17B10 Q99714 3/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ HTT P42858 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27161574 0.89 CYP3A4 (0.51) GAAKDM4ECYP2D6ALDH1A1SMN1; SMN2
SCHEMBL27162351 0.88 GAA (0.48) GAAKDM4ECYP2D6ALDH1A1SMN1; SMN2
SCHEMBL27162149 0.86 GAA (0.50) GAAKDM4ECYP2D6ALDH1A1SMN1; SMN2
SCHEMBL27161599 0.83 CYP2D6 (0.50) GAAKDM4ECYP2D6ALDH1A1USP2
SCHEMBL30049556 0.83 CYP2D6 (0.50) GAAKDM4ECYP2D6ALDH1A1USP2
SCHEMBL30050317 0.83 CYP2D6 (0.56) GAAKDM4ECYP2D6ALDH1A1SMN1; SMN2
SCHEMBL27162898 0.83 CYP2D6 (0.56) GAAKDM4ECYP2D6ALDH1A1SMN1; SMN2
SCHEMBL27162113 0.82 GAA (0.45) GAAKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL27162293 0.78 GAA (0.47) GAAKDM4ECYP2D6ALDH1A1SMN1; SMN2
SCHEMBL27161915 0.78 GAA (0.47) GAAKDM4ECYP2D6ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US claimed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP claimed
WO-2022229405-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS ACONDICIONAMIENTO TARRASENSE (ES) 2022-11-03 — — WO claimed
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US disclosed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP disclosed
WO-2022229405-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS ACONDICIONAMIENTO TARRASENSE (ES) 2022-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands SIGMAR1, TMEM97, OPRD1 GAA 3700/4885KDM4E 3959/4885CYP2D6 514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback